Open Payments

RACHEL HUCKFELDT

Type
Physician · Allopathic & Osteopathic Physicians / Ophthalmology
Where
STONEHAM, MA
NPI
1205160173
Received
$38,951 in 57 records, 2019 to 2025 ($38,940 general, $11 research)
As principal investigator
$1,693,128 of research payments to others in 76 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment3$8,534
2024General payment14$13,511
2023General payment30$12,238
2022General payment2$200
2021General payment1$4,320
2019General payment6$135
2019Research payment1$11

By company

CompanyRecordsAmountYears
Janssen Pharmaceuticals, Inc39$25,1542023–2025
SANOFI US SERVICES INC.2$5,2382023
Regeneron Pharmaceuticals, Inc.1$4,3202021
Sumitomo Pharma America, Inc.4$3,7702023–2024
Spark Therapeutics, Inc.4$2982019–2023
Janssen Global Services, LLC1$1142022
Inspire Medical Systems, Inc.1$242025
Regeneron Healthcare Solutions, Inc.1$182019
Allergan, Inc.1$112019
Travere Therapeutics, Inc.3$22019

By nature of payment

NatureRecordsAmount
Consulting Fee14$32,519
Travel and Lodging19$5,220
Food and Beverage19$1,179
Education4$20
Research payment1$11

Records

DateCompanyAmountNatureFormProductStudyYear
2025-06-24Janssen Pharmaceuticals, Inc$370Consulting FeeCash or cash equivalent2025
2025-05-16Inspire Medical Systems, Inc.$24Food and BeverageIn-kind items and servicesINSPIRE Device, NEUROLOGY2025
2025-01-30Janssen Pharmaceuticals, Inc$8,140Consulting FeeCash or cash equivalent2025
2024-11-25Janssen Pharmaceuticals, Inc$1,110Consulting FeeCash or cash equivalent2024
2024-10-20Janssen Pharmaceuticals, Inc$44Food and BeverageIn-kind items and services2024
2024-10-20Janssen Pharmaceuticals, Inc$32Food and BeverageIn-kind items and services2024
2024-10-20Janssen Pharmaceuticals, Inc$17Food and BeverageIn-kind items and services2024
2024-10-03Sumitomo Pharma America, Inc.$650Consulting FeeCash or cash equivalent2024
2024-09-25Janssen Pharmaceuticals, Inc$716Travel and LodgingIn-kind items and services2024
2024-09-25Janssen Pharmaceuticals, Inc$173Travel and LodgingIn-kind items and services2024
2024-09-25Janssen Pharmaceuticals, Inc$173Travel and LodgingIn-kind items and services2024
2024-07-29Janssen Pharmaceuticals, Inc$1,110Consulting FeeCash or cash equivalent2024
2024-07-29Janssen Pharmaceuticals, Inc$370Consulting FeeCash or cash equivalent2024
2024-06-18Janssen Pharmaceuticals, Inc$2,220Consulting FeeCash or cash equivalent2024
2024-06-13Sumitomo Pharma America, Inc.$975Consulting FeeCash or cash equivalent2024
2024-02-07Janssen Pharmaceuticals, Inc$5,180Consulting FeeCash or cash equivalent2024
2024-02-07Janssen Pharmaceuticals, Inc$740Consulting FeeCash or cash equivalent2024
2023-12-10Janssen Pharmaceuticals, Inc$123Travel and LodgingIn-kind items and services2023
2023-12-10Janssen Pharmaceuticals, Inc$123Travel and LodgingIn-kind items and services2023
2023-12-10Janssen Pharmaceuticals, Inc$123Travel and LodgingIn-kind items and services2023
2023-12-10Janssen Pharmaceuticals, Inc$123Travel and LodgingIn-kind items and services2023
2023-12-10Janssen Pharmaceuticals, Inc$55Food and BeverageIn-kind items and services2023
2023-12-10Janssen Pharmaceuticals, Inc$55Food and BeverageIn-kind items and services2023
2023-12-10Janssen Pharmaceuticals, Inc$55Food and BeverageIn-kind items and services2023
2023-12-10Janssen Pharmaceuticals, Inc$20Food and BeverageIn-kind items and services2023
2023-12-10Janssen Pharmaceuticals, Inc$20Food and BeverageIn-kind items and services2023
2023-12-10Janssen Pharmaceuticals, Inc$20Food and BeverageIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$196Travel and LodgingIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$196Travel and LodgingIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$196Travel and LodgingIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$196Travel and LodgingIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$140Travel and LodgingIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$140Travel and LodgingIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$140Travel and LodgingIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$140Travel and LodgingIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$125Food and BeverageIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$125Food and BeverageIn-kind items and services2023
2023-12-09Janssen Pharmaceuticals, Inc$125Food and BeverageIn-kind items and services2023
2023-11-21Janssen Pharmaceuticals, Inc$578Travel and LodgingIn-kind items and services2023
2023-11-21Janssen Pharmaceuticals, Inc$578Travel and LodgingIn-kind items and services2023
2023-11-21Janssen Pharmaceuticals, Inc$578Travel and LodgingIn-kind items and services2023
2023-11-21Janssen Pharmaceuticals, Inc$578Travel and LodgingIn-kind items and services2023
2023-09-12SANOFI US SERVICES INC.$5,189Consulting FeeCash or cash equivalent2023
2023-09-12SANOFI US SERVICES INC.$49Food and BeverageIn-kind items and services2023
2023-05-11Sumitomo Pharma America, Inc.$845Consulting FeeCash or cash equivalent2023
2023-04-24Spark Therapeutics, Inc.$97Food and BeverageIn-kind items and servicesLUXTURNA Biological, OCULAR2023
2023-03-30Sumitomo Pharma America, Inc.$1,300Consulting FeeCash or cash equivalent2023
2022-09-30Janssen Global Services, LLC$114Food and BeverageIn-kind items and services2022
2022-05-03Spark Therapeutics, Inc.$86Food and BeverageIn-kind items and servicesLUXTURNA Biological, OCULAR2022
2021-12-17Regeneron Pharmaceuticals, Inc.$4,320Consulting FeeCash or cash equivalentEYLEA Biological, OPHTHALMOLOGY2021
2019-12-16Travere Therapeutics, Inc.$0EducationIn-kind items and services(820) Cholbam Drug, Hepatology2019
2019-11-06Travere Therapeutics, Inc.$0EducationIn-kind items and services(820) Cholbam Drug, Hepatology2019
2019-10-13Spark Therapeutics, Inc.$76Food and BeverageIn-kind items and servicesLUXTURNA Biological, OCULAR2019
2019-04-30Allergan, Inc.$11Research paymentIn-kind items and servicesOpen-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pedi2019
2019-04-29Spark Therapeutics, Inc.$37Food and BeverageIn-kind items and servicesLUXTURNA Biological, OCULAR2019
2019-03-11Travere Therapeutics, Inc.$0EducationIn-kind items and services(820) Cholbam Drug, Hepatology2019
2019-02-28Regeneron Healthcare Solutions, Inc.$18EducationIn-kind items and servicesEYLEA Biological, OPHTHALMOLOGY2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-15Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$72,312An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-12-11Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$5,552Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-11-13Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$4,764Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-10-27Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$7,637An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-10-15Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$12,689Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-09-18Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$5,465Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-08-27Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$2,800Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-08-06Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$10,229Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-08-06Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$27,706Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-07-21Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$4,040An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-06-30Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$6,498An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-06-24Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$1,000Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene2025
2025-06-12Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$1,216An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-06-02Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$25,366An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-06-02Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$2,241An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-06-02Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$1,549An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-05-31Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$15,078Long-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-05-31Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$8,166Long-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-05-31Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$20,978Long-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-05-28Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$1,950Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene2025
2025-05-22Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$8,529Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene2025
2025-05-08Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$120Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-05-02Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$7,001An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-04-03Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$27,466Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-04-03Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$1,152Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-03-28Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$3,727An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-02-24Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$24,400An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom2025
2025-01-31Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$1,901Long-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$6,106Long-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$2,479Long-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$28,469Long-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$14,035Long-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-31Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$4,951Long-term Follow-up Gene Therapy Study for RPGR- XLRP2025
2025-01-30Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$185,164Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene2025
2025-01-16Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$35,132Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gen2025
2025-01-16Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$929Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene2025
2024-12-05Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$1,795MGT-RPGR-0222024
2024-11-27Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$2,500MGT-RPGR-0212024
2024-11-27Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$5,179MGT-RPGR-0222024
2024-11-27Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$5,100MGT-RPGR-0212024
2024-11-14Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$60MGT-RPGR-0222024
2024-10-04Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$5,576MGT-RPGR-0212024
2024-10-04Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$70,373MGT-RPGR-0222024
2024-08-08Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$2,940MGT0212024
2024-07-18Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$8,419MGT0212024
2024-05-09Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$51,284MGT-RPGR-0222024
2024-04-25Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$629MGT0212024
2024-04-18Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$700MGT-RPGR-0222024
2024-04-04Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$2,942MGT-RPGR-0222024
2024-03-27Biogen, Inc.Massachusetts Eye And Ear Infirmary$7,664A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia P2024
2024-03-14Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$100,047MGT0212024
2024-03-14Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$3,500MGT0212024
2024-03-14Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$14,813MGT0212024
2024-03-14Janssen Research & Development, LLCMa Eye and Ear Infrmry Mri$52,942MGT-RPGR-0222024
2023-10-04Janssen Research & Development, LLCMassachusetts Eye And Ear Infirmary$474,516MGT0212023
2023-07-06Novartis Pharmaceuticals CorporationMassachusetts Eye & Ear Infirmary$2,568Identifying patients and understanding endpoints in severe visual impairment due to primary outer retinal degeneration2023
2023-03-21Biogen, Inc.Massachusetts Eye And Ear Infirmary$5,222A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Re2023
2023-03-20Biogen, Inc.Massachusetts Eye And Ear Infirmary$12,491An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-2023
2023-01-09Biogen, Inc.Massachusetts Eye And Ear Infirmary$7,703A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia P2023
2022-10-13Biogen, Inc.MASSACHUSETTS EYE AND EAR INFIRMARY$16,055A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia P2022
2022-02-07Biogen, Inc.MASSACHUSETTS EYE AND EAR INFIRMARY$26,848An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-2022
2021-01-25Biogen, Inc.Massachusetts Eye And Ear Infirmary$110,238An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-2021
2020-10-22Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$30,911A PHASE 1/2 SAFETY STUDY IN SUBJECTS WITH CHM (CHOROIDEREMIA) GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 2020
2020-08-03Biogen, Inc.MASS EYE & EAR INFIRMARY$37,216An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-2020
2019-11-30Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-10-31Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-09-30Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-08-31Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-08-06Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$34,797A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-07-31Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-06-30Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-05-31Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-04-30Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-03-31Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-02-28Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019
2019-01-31Spark Therapeutics, Inc.MASS EYE & EAR INFIRMARY$843A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VEC2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Middlesex CountyStoneham CDP

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Stoneham, MA, county Middlesex County, MA, state Massachusetts; placed by its city name.

MeasurePlace (city or town)
Stoneham, MA
County
Middlesex County, MA
State
Massachusetts
Population B0100323,3551,638,3657,044,056
Population, 2020 census P123,2441,632,0027,029,917
Median age B0100242.238.940.0
Under 18 B0100120.8%19.5%19.4%
65 and over B0100120.4%16.3%17.9%
Households B110019,749634,2152,785,042
Foreign born B0500211.7%23.1%18.0%
Median household income B19013$113,964$130,847$103,960
Median family income B19113$159,885$166,449$131,675
Per capita income B19301$62,866$69,556$57,897
Poverty rate B170015.4%7.7%10.0%
Unemployment rate B230252.2%4.4%5.2%
Civilian labor force B2302513,180946,9893,911,446
Mean commute (minutes) B0801327.829.929.1
Bachelor's degree or higher B1500355.9%59.5%47.3%
Housing units B2500110,196664,2673,030,406
Owner-occupied B2500371.0%61.3%62.5%
Renters B2500329.0%38.7%37.5%
Median home value B25077$671,900$727,800$562,100
Median gross rent B25064$2,035$2,201$1,762
White, not Hispanic B0300281.0%65.1%66.6%
Black B030021.2%4.7%6.4%
Hispanic or Latino B030024.7%9.3%13.3%
Asian B030026.8%13.6%7.3%
American Indian and Alaska Native B030020.0%0.1%0.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stoneham, MA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.